AsiDNA is under clinical development by Onxeo and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AsiDNA’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AsiDNA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AsiDNA overview

AsiDNA (DT-01) is under development for the treatment of solid tumors including triple negative breast cancer, head and neck cancer, non-small cell lung cancer, gastric cancer, high grade glioma, metastatic liver cancer and ovarian cancer, colorectal cancer and for other targeted therapies, breast cancer, epithelial ovarian cancer and metastatic castration-resistant prostate cancer (mCRPC). The drug candidate is administered through subcutaneous, intratumoral and intravenous route. It belongs to the Dbait (double-strand breaks (DSBs) family. Dbait is a 5' cholesterol-Dbait conjugate. Dbaits are specifically designed and selected according to signal interfering DNA (siDNA) concept to inhibit DSB repair. It is developed by using siDNA (signal interfering DNA) technology.

It was also under development for the treatment of metastatic melanoma.

Onxeo overview

Onxeo is a clinical-stage biotechnology company. The company is a manufacturer of drugs that offers the development and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products including beleodaq and asidna among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer among others. In addition, the company’s beleodaq acts as an anti-cancer treatment for solid and hematology cancer. The company provides preclinical and clinical development, regulatory affairs and other services. Onxeo is headquartered in Paris, France.

Quick View AsiDNA LOA Data

Report Segments
  • Innovator
Drug Name
  • AsiDNA
Administration Pathway
  • Intratumor
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Oncology
  • Undisclosed
Key Developers
  • Sponsor Company: Onxeo
  • Originator: DNA Therapeutics
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.